Lobbying disclosures · Lobbying report
LLY: third_quarter 2026 lobbying report
Health insurance accessibility. Artificial Intelligence in health care. Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act. Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.
Follow LLY- Became public
- Oct 20, 2026, 6:45 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 12, 2026, 12:07 AM EST
Why this is connected
Legal-name match: ELI LILLY AND COMPANY is ELI LILLY & Co (https://www.sec.gov/Archives/edgar/data/59478/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $80,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/f44b3137-aec1-41dc-b591-d1a88ed8357b/","filing_uuid":"f44b3137-aec1-41dc-b591-d1a88ed8357b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/f44b3137-aec1-41dc-b591-d1a88ed8357b/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-20T18:45:20-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":55430,"url":"https://lda.gov/api/v1/clients/55430/","client_id":55430,"name":"ELI LILLY AND COMPANY","general_description":"American pharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Health insurance accessibility. Artificial Intelligence in health care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee","new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander","new":false},{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker","new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie","new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":"Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in LLY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Oct 20, 2026 · disclosed Nov 10, 2026
Traded 9 days before earnings - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Jul 1, 2026 · disclosed Aug 7, 2026
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Jan 2, 2026 · disclosed Aug 7, 2026 · filed 217 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Dec 2, 2025 · disclosed Aug 7, 2026 · filed 248 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Sold (full) Eli Lilly and Company LLY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 17, 2026$1K–$15K
Rep. Dan Newhouse (R-WA-4)
Sold (partial) Eli Lilly and Company LLY
$1K–$15K · Traded Jul 10, 2026 · disclosed Jul 17, 2026 · Spouse
- Jul 2, 2026$50K–$100K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$50K–$100K · Traded Jun 10, 2026 · disclosed Jul 2, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.